Abbott challenges copies of its biologic drugs
08:19 EDT 22 Jun 2012 | The Medical News
If the challenge succeeds, less-expensive versions of complex biologic drugs couldn't go on sale in the U.S. for years, and consumers may never have access to facsimiles of existing treatments such as Abbott's rheumatoid arthritis therapy Humira.
Original Article: Abbott challenges copies of its biologic drugs
More From BioPortfolio on "Abbott challenges copies of its biologic drugs"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
